Table 1 Baseline characteristics
From: Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
Patients, number | 21 | ||
Gender male/female | 1 | / | 20 |
Age, years | 52 | ± | 18 |
Height, cm | 165 | ± | 6 |
Weight, kg | 68 | ± | 11 |
WHO functional class, number (%) | |||
II | 9 | (43) | |
III | 7 | (33) | |
IV | 5 | (24) | |
Lung function | |||
TLCO, % | 55 | ± | 18 |
FEV1%VC, % | 78 | ± | 7 |
pO2, mmHg | 69 | ± | 12 |
Mean 6-minute-walking distance, meter | |||
386 | ± | 121 | |
Differential Diagnosis, number (%) | |||
Systemic sclerosis | 8 | (43%) | |
Systemic lupus | 7 | (33%) | |
MCTD | 2 | (10%) | |
Others | 4 | (14%) | |
Cardiac catherization | |||
Pulmonary artery pressure, mmHg | 49 | ± | 13 |
Pulmonary vascular resistance, dyn×sec×cm-5 | 789 | ± | 498 |
Right atrium pressure, mmHg | 7 | ± | 3 |
Pulmonary artery oxygen saturation, % | 62 | ± | 10 |
PCWP, mmHg | 10 | ± | 5 |
Cardiac index, L×min×m-2 | 2.6 | ± | 0.6 |
PAH-targeted medication, number (%) | |||
Endothelin receptor antagonists | 12 | (57%) | |
Phosphodiesterase-5-Inhibitors | 15 | (71%) | |
Prostanoids inhaled | 3 | (14%) | |
Prostanoids intravenous | 1 | (5%) | |
Calcium channel blockers | 2 | (10%) | |
Soluble guanyl cyclase-stimulator | 3 | (14%) | |
Combination therapy, number (%) | |||
Monotherapy | 8 | (38%) | |
Dual therapy | 10 | (48%) | |
Triple therapy | 3 | (14%) | |